Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer

doi:10.5306/wjco.v7.i5.340

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 5

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7270)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

528

WORD

414

HTML

3663

Figures (1-2)

249

Tables (1-1)

246

Sum=5100

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

922

Download

1248

Sum=2170

Oct 10, 2016 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Clin Oncol. Oct 10, 2016; 7(5): 340-351
Published online Oct 10, 2016. doi: 10.5306/wjco.v7.i5.340

Full Size Figure Download Figure

Figure 2 Possible resistance pathways to epidermal growth factor receptor blockade; gain of mutations in KRAS, BRAF, and PIK3CA and upregulation of other receptor tyrosine kinases. EGFR: Epidermal growth factor receptor; mTOR: Mechanistic target of rapamycin; PI3KCA: Phosphotidylinositol-3-kinase.

Citation: Sobani ZA, Sawant A, Jafri M, Correa AK, Sahin IH. Oncogenic fingerprint of epidermal growth factor receptor pathway and emerging epidermal growth factor receptor blockade resistance in colorectal cancer. World J Clin Oncol 2016; 7(5): 340-351
URL: https://www.wjgnet.com/2218-4333/full/v7/i5/340.htm
DOI: https://dx.doi.org/10.5306/wjco.v7.i5.340